CN106535940A - 用于癌症治疗的溶瘤病毒和极光激酶抑制剂 - Google Patents

用于癌症治疗的溶瘤病毒和极光激酶抑制剂 Download PDF

Info

Publication number
CN106535940A
CN106535940A CN201580038192.8A CN201580038192A CN106535940A CN 106535940 A CN106535940 A CN 106535940A CN 201580038192 A CN201580038192 A CN 201580038192A CN 106535940 A CN106535940 A CN 106535940A
Authority
CN
China
Prior art keywords
oncolytic
virus
hsv1716
aurora kinase
mln8237
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580038192.8A
Other languages
English (en)
Chinese (zh)
Inventor
J路搴风撼
J·康纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virttu Biologics Ltd
Original Assignee
Virttu Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virttu Biologics Ltd filed Critical Virttu Biologics Ltd
Publication of CN106535940A publication Critical patent/CN106535940A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201580038192.8A 2014-05-12 2015-05-07 用于癌症治疗的溶瘤病毒和极光激酶抑制剂 Pending CN106535940A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1408297.8A GB201408297D0 (en) 2014-05-12 2014-05-12 Treatment of cancer
GB1408297.8 2014-05-12
PCT/GB2015/051347 WO2015173544A1 (en) 2014-05-12 2015-05-07 Oncolytic virus and aurora kinase inhibitor for the treatment of cancer

Publications (1)

Publication Number Publication Date
CN106535940A true CN106535940A (zh) 2017-03-22

Family

ID=51032548

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580038192.8A Pending CN106535940A (zh) 2014-05-12 2015-05-07 用于癌症治疗的溶瘤病毒和极光激酶抑制剂

Country Status (6)

Country Link
US (1) US20170071991A1 (https=)
EP (1) EP3142677A1 (https=)
JP (1) JP2017515847A (https=)
CN (1) CN106535940A (https=)
GB (1) GB201408297D0 (https=)
WO (1) WO2015173544A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019062250A1 (zh) * 2017-09-28 2019-04-04 杭州康万达医药科技有限公司 包含分离的重组溶瘤腺病毒和nk细胞的治疗剂及应用、药盒、治疗肿瘤和/或癌症的方法
WO2019129234A1 (zh) * 2017-12-29 2019-07-04 广州威溶特医药科技有限公司 极光激酶抑制剂和甲病毒在制备抗肿瘤药物的应用
CN116004567A (zh) * 2022-12-07 2023-04-25 北京大学 极光激酶b基因k202突变及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085890A1 (en) * 2016-07-29 2020-03-19 Ohio State Innovation Foundation Expression of pten-long with ocolytic viruses
US11357776B2 (en) 2016-10-28 2022-06-14 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof
CN110869052A (zh) * 2016-12-23 2020-03-06 维图生物制剂公司 癌症的治疗

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135641A2 (en) * 2011-03-30 2012-10-04 H. Lee Moffitt Cancer Center And Research Institute Aurora kinase inhibitors and methods of making and using thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6309274B2 (ja) * 2011-03-11 2018-04-11 ターンストーン・リミテッド・パートナーシップ ヒストンデアセチラーゼ阻害剤を含むワクチン接種法
US9056133B2 (en) * 2011-05-25 2015-06-16 Cti-S.A. Pharmaceutical kit and method for treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135641A2 (en) * 2011-03-30 2012-10-04 H. Lee Moffitt Cancer Center And Research Institute Aurora kinase inhibitors and methods of making and using thereof

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019062250A1 (zh) * 2017-09-28 2019-04-04 杭州康万达医药科技有限公司 包含分离的重组溶瘤腺病毒和nk细胞的治疗剂及应用、药盒、治疗肿瘤和/或癌症的方法
US11806374B2 (en) 2017-09-28 2023-11-07 Hangzhou Converd Co., Ltd. Isolated recombinant oncolytic adenoviruses, pharmaceutical compositions, and uses thereof for drugs for treatment of tumors and/or cancers
WO2019129234A1 (zh) * 2017-12-29 2019-07-04 广州威溶特医药科技有限公司 极光激酶抑制剂和甲病毒在制备抗肿瘤药物的应用
CN109985239A (zh) * 2017-12-29 2019-07-09 广州威溶特医药科技有限公司 极光激酶抑制剂和甲病毒在制备抗肿瘤药物的应用
TWI722357B (zh) * 2017-12-29 2021-03-21 大陸商廣州威溶特醫藥科技有限公司 極光激酶抑制劑和α病毒用於製備抗腫瘤藥物之用途
CN109985239B (zh) * 2017-12-29 2024-10-18 广州威溶特医药科技有限公司 极光激酶抑制剂和甲病毒在制备抗肿瘤药物的应用
CN116004567A (zh) * 2022-12-07 2023-04-25 北京大学 极光激酶b基因k202突变及其应用

Also Published As

Publication number Publication date
JP2017515847A (ja) 2017-06-15
EP3142677A1 (en) 2017-03-22
WO2015173544A1 (en) 2015-11-19
US20170071991A1 (en) 2017-03-16
GB201408297D0 (en) 2014-06-25

Similar Documents

Publication Publication Date Title
CN106535940A (zh) 用于癌症治疗的溶瘤病毒和极光激酶抑制剂
Portella et al. Aurora B: a new prognostic marker and therapeutic target in cancer
Chakrabarty et al. The oncolytic virus, pelareorep, as a novel anticancer agent: a review
US10799560B2 (en) HSV vectors for delivery of NT3 and treatment of CIPN
Singh et al. Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR-ErbB2 signaling with lapatinib
EP3325488A1 (en) Chiral diaryl macrocycles and uses thereof
Zhang et al. An effective drug sensitizing agent increases gefitinib treatment by down regulating PI3K/Akt/mTOR pathway and up regulating autophagy in non-small cell lung cancer
CN107530336B (zh) 组合使用mdm2抑制剂和btk抑制剂的治疗方法
Luzzi et al. Targeting the medulloblastoma: A molecular-based approach
AU2019315550A1 (en) Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof
US12385067B2 (en) Compositions and therapeutic methods of microRNA gene delivery
KR20190097240A (ko) 종양용해성 바이러스 및 치료 분자
Macarulla et al. Aurora kinase family: a new target for anticancer drug
KR20230066401A (ko) 항종양 치료법에서 면역 체크포인트 억제제와 조합된 치아우라닙의 용도
de Almeida Magalhães et al. The therapeutic potential of Aurora kinases targeting in glioblastoma: from preclinical research to translational oncology
JP2018518986A (ja) 腫瘍溶解性ｈｓｖ１ベクターおよび使用法
Rothkamm et al. Radiosensitisation and enhanced tumour growth delay of colorectal cancer cells by sustained treatment with trifluridine/tipiracil and X-rays
Pérez Fidalgo et al. Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system
Frosina Frontiers in targeting glioma stem cells
CN112996503A (zh) P53 wt肿瘤的治疗方法
US20240277792A1 (en) Oncolytic viruses and methods of use thereof for the treatment of cancer
Molina-Alvarez et al. PARP-1 and PARP-2 in B-cell Lymphoma: Pathogenic Roles and Therapeutic Implications
CN114096661A (zh) 改进了安全性及抗肿瘤效果的溶瘤病毒
Smith Silencing stemness genes in Glioblastoma cancer stem cells improve anticancer drug efficacy
Hawkins Radioresistance and radiosensitization in high-risk Group 3 pediatric medulloblastoma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170322

WD01 Invention patent application deemed withdrawn after publication